KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Opko Health (OPK) over the last 16 years, with Sep 2025 value amounting to $415.2 million.

  • Opko Health's Cash & Equivalents rose 2.16% to $415.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.2 million, marking a year-over-year increase of 2.16%. This contributed to the annual value of $431.9 million for FY2024, which is 350.49% up from last year.
  • Opko Health's Cash & Equivalents amounted to $415.2 million in Q3 2025, which was up 52.80% from $271.7 million recorded in Q2 2025.
  • Opko Health's 5-year Cash & Equivalents high stood at $436.0 million for Q1 2025, and its period low was $40.6 million during Q2 2024.
  • Its 3-year average for Cash & Equivalents is $230.1 million, with a median of $138.6 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 839.27% in 2021, then crashed by 62.47% in 2024.
  • Quarterly analysis of 5 years shows Opko Health's Cash & Equivalents stood at $134.7 million in 2021, then climbed by 13.72% to $153.2 million in 2022, then plummeted by 37.41% to $95.9 million in 2023, then surged by 350.49% to $431.9 million in 2024, then increased by 2.16% to $415.2 million in 2025.
  • Its Cash & Equivalents stands at $415.2 million for Q3 2025, versus $271.7 million for Q2 2025 and $436.0 million for Q1 2025.